73 results
424B5
STOK
Stoke Therapeutics Inc
28 Mar 24
Prospectus supplement for primary offering
5:15pm
federal government shutdown, on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research … and development costs, clinical trials and employees;
our ability to develop, obtain regulatory approval for and commercialize STK-001, STK-002
424B5
STOK
Stoke Therapeutics Inc
26 Mar 24
Prospectus supplement for primary offering
4:47pm
, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees … ability to protect our intellectual property, business strategies, market size, potential growth opportunities, prospective products, research
8-K
EX-99.1
fan6dpq c3fm81f3a
25 Mar 24
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:03pm
SC TO-I/A
am8u15 fdf425
17 Nov 23
Issuer tender offer statement (amended)
4:37pm
8-K
EX-99.1
fsyiwsx
7 Nov 23
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
zq14f3zzppvp5zysi
7 Aug 23
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
ufuxsxezkpygu91 gth7
4 May 23
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am
PRE 14A
ertj 13pio7a1f9fro
17 Apr 23
Preliminary proxy
4:01pm
S-8
EX-99.1
urxsmnke vtbn
13 Apr 23
Registration of securities for employees
4:02pm
8-K
EX-99.1
ma25h8q 77olfqgts
14 Nov 22
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
yhzj9n
8 Aug 22
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:05am